GlassScriptPhysician profile
Theodore A Schiff
NPI 1043276124
$3,051.43
in general payments reported to CMS, 2019-2025
26 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $349 · 2021: $210 · 2022: $357 · 2023: $357 · 2024: $1,239 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $620.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,065.97 | 2019-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $331.17 | 2019-2025 | |
| Janssen Biotech, INC. | $233.94 | 2020-2024 | Tremfya |
| Allergan, INC. | $209.04 | 2019-2022 | |
| Medtronic, INC. | $177.75 | 2024 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $146.47 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $142.23 | 2019-2024 | Dupixent |
| Leo Pharma INC. | $82.93 | 2019-2022 | |
| Pfizer INC. | $79.31 | 2022-2023 | |
| Kerecis Limited | $72.27 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Merz North America, INC. | $65.90 | 2021 | |
| Boston Scientific Corporation | $55.00 | 2024 | Varithena Administration Pack |
| Sun Pharmaceutical Industries INC. | $52.74 | 2022 | |
| Ucb, INC. | $43.10 | 2024 | Bimzelx |
| Strata Skin Sciences, INC. | $37.00 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.76 | 2020-2025 | |
| Incyte Corporation | $33.48 | 2023-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $26.98 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $25.30 | 2020 | |
| Almirall LLC | $24.71 | 2024 | Klisyri |
| Smith+Nephew, INC. | $23.71 | 2025 | Collagenase Santyl |
| Galderma Laboratories, L.P. | $22.33 | 2020 | |
| Horizon Therapeutics Plc | $19.47 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.24 | 2020 | |
| Triad Life Sciences INC. | $13.88 | 2022 | |
| Organon LLC | $10.75 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Schiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.